Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ALAlkermes plc logo

Alkermes plc (ALKS)

NASDAQ · Currency in USD
$43.63 ▼ -0.55 (-1.24%)
At close: Oct 23, 4:00 PM ET. Market closed.
$43.63 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$44.18
Open
$44.15
Day's Range
$43.16 – $44.15
52 Week Range
$27.00 – $55.67
Volume
884,392
Avg. Volume
2,067,804
Market Cap
$7.32B
Beta (5Y Monthly)
0.27
PE Ratio (TTM)
108.26
EPS (TTM)
$0.40
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$58.29

Profile: Alkermes plc

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
2,050
CEO
Blair Jackson

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.08 · Revenue est. $463.60M
DateEst.Actual
Jul 28, 2026-$0.03$0.70Beat
May 5, 2026-$0.57-$0.40Beat
Feb 25, 2026$0.43$0.34Miss
Oct 28, 2025$0.37$0.49Beat
Jul 29, 2025$0.41$0.52Beat
May 1, 2025$0.25$0.13Miss

Analyst view

Consensus price target
$58.29 ▲ +33.6%
Range $50.00 – $65.00
Rating: Buy
Buy 55% · Hold 34% · Sell 10%

Get free alerts on ALKS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.